Latest News

Michael Flanagan, PhD, on Del-zota’s Breakthrough Potential for Duchenne Muscular Dystrophy
Michael Flanagan, PhD, on Del-zota’s Breakthrough Potential for Duchenne Muscular Dystrophy

April 17th 2025

The chief scientific officer at Avidity Biosciences details the mechanism, early results, and future plans for Del-zota, an investigational therapy targeting exon 44 in Duchenne muscular dystrophy.

miRNA-214 Shows Potential as Biomarker to Predict ALS Disease Progression
miRNA-214 Shows Potential as Biomarker to Predict ALS Disease Progression

April 17th 2025

Rajinder Bhardwaj, PhD  (Credit: Certara)
Migraine Treatment Zavegepant Shows No Meaningful Impact on Oral Contraceptive Exposure

April 17th 2025

A Clinician’s Perspective on First-in-Human Data for LRRK2 Degrader ARV-102
A Clinician’s Perspective on First-in-Human Data for LRRK2 Degrader ARV-102

April 16th 2025

Lisette Kogelman, MSc  (Credit: LinkedIn)
Large Danish Cohort Study Reveals No Significant Association Between HLA Alleles and Migraine

April 16th 2025

Coverage of the 2025 AAN Annual Meeting

Get direct access to interviews with experts, as well as the latest data and clinical news updates, straight from the conference floor in San Diego.

AAN 2025

Conference Coverage

View All
Michael Flanagan, PhD, on Del-zota’s Breakthrough Potential for Duchenne Muscular Dystrophy
Michael Flanagan, PhD, on Del-zota’s Breakthrough Potential for Duchenne Muscular Dystrophy

April 17th 2025

Bruce Bebo, PhD
Celebrating Innovation in MS Research With the John Dystel Prize: Bruce Bebo, PhD

April 17th 2025

James Beck, PhD
Expanding Access to Whole Genome Sequencing in Parkinson Research: James Beck, PhD

April 17th 2025

A Clinician’s Perspective on First-in-Human Data for LRRK2 Degrader ARV-102
A Clinician’s Perspective on First-in-Human Data for LRRK2 Degrader ARV-102

April 16th 2025

Video Series
Video Interviews
Podcasts

Most Recent

© 2025 MJH Life Sciences

All rights reserved.